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signiﬁcantly thickened compared to sham knee joints at 8 weeks after
surgery. In contrast, strain 6 mice showed thinning at all time points
(Figure 1B). Strain 6 mice showed signiﬁcantly lower bone volume
fraction at all time points, while in strain 33 mice bone volume was
lower only at 4 weeks and reversed from 4 to 8 weeks. Trabecular
thickness was less in strain 6 mice at all time points, but only at 4 weeks
in strain 33 mice with thickening at 8 weeks. The trabecular connective
density, which calculates the number of trabecular bone connections,
showed strain 33 mice looses trabecular bone at 4 weeks and thickens
by 8 weeks after surgery, while trabecular bone loss was observed in all
time points in strain 6 mice.
Conclusions: Strain 33 mice, which have poor healing ability for soft
tissues like ear hole, demonstrated a natural history of OA development:
they initially have bone loss, then cartilage loss followed by bone sclerosis
in the late stage of OA. In contrast, strain 6 mice, which have a good
healing ability in tissue, were protected against OA and showed bone
loss in all time points. These results suggest that cartilage and bone
changes associated with OA development are linked each other and
suggest that cartilage loss leads to subchondral bone thickening. In other
studies currently underway in our laboratory, we have found that strain
6 can repair a full thickness cartilage injury, while strain 33 cannot repair
its cartilage (Table 1). Therefore, our studies demonstrate a signiﬁcant
correlation between ear punch healing, cartilage repair and resistance to
OA in these genetic strains of mice.
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Purpose: To evaluate the symptom- and structure-modifying efﬁcacy and
safety of oral salmon calcitonin (oCT) formulated with a 5-CNAC carrier
(a molecule based on Eligen® technology from Emisphere), in patients
with moderate to severe knee pain and structural damages classiﬁed as
Kellgren-Lawrence 2–3 due to osteoarthritis (OA).
Methods: A total of 1169 men and women aged 50–80 years with
a mean BMI of 28.9 kg/m2 who had painful OA of the knee with
structural manifestations were enrolled in this multi-center, double-
blind, randomized placebo-controlled study. Patients received (1:1) oCT
0.8mg twice daily or placebo for 24 months; rescue medication was
allowed in both arms. The primary efﬁcacy endpoints were joint-space
width (JSW), WOMAC pain and function visual analogue scale scores after
24 months in the signal knee. Secondary endpoints included but were not
limited to WOMAC stiffness, patient and physician global assessments,
and knee cartilage degradation. Safety endpoints were adverse events
(AEs) and tolerability.
Results: Baseline values were well matched between the two groups.
In ITT analysis at 24 months, oCT treatment did not have an effect
on JSW (p=0.97; progression was −0.2mm in both groups). However,
oCT increased cartilage volume by a mean 4.8% (0.73%) [vs 2.5% (0.61%)
in placebo group, p = 0.012]. Furthermore, oCT resulted in signiﬁcant
changes (vs placebo) in WOMAC pain [−115.7 (4.9) vs −94.9 (4.8) mm;
p=0.002], function [−338.7 (16.7) vs −283.0 (15.8) mm; p=0.013] (see
Figure) and stiffness [−44.1 (2.2) vs −32.6 (2.1) mm; p < 0.001] scores
(numbers in parentheses are standard errors). Improvement was also
obtained in the oCT group (vs placebo) in VAS 24 hour pain (p = 0.018),
patient global assessment (p =0.008) and physician global assessment
(p = 0.014). The discontinuation rate was 33% for oCT vs 23% for placebo
treatment. Drug-related AE discontinuations occurred in 19.5% oCT group
(vs 5.8% in placebo group), mostly happening early in the oCT group
then parallel to placebo. The most common AEs in the oCT group (vs
placebo) were hot ﬂush (17.8 vs 4.1%), nausea (14 vs 3.1%), dyspepsia
(10.1 vs 4.5%) and diarrhoea (9.6 vs 4.3%), and accounted for most
discontinuations. Immunogenicity was noted in 17.4% (oCT) vs 1.6%
(placebo) at 24 months.
Figure: Select efﬁcacy variables: mean changes over two years.
Conclusions: Twice daily oCT over 2 years resulted in a signiﬁcant
symptom-modifying efﬁcacy in patients with painful knee OA as assessed
by WOMAC pain, physical function, and stiffness scores. Although
improvement on the primary endpoint of JSW was not reached, there
was an increase in cartilage volume vs placebo indicating some structure-
modifying efﬁcacy. Safety and tolerability of oCT was largely in line with
previous clinical experience with calcitonins.
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A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED,
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Purpose: There are no disease-modifying OA drugs (DMOAD) – a
continuing unmet need. In OA, levels of growth factors (key regulators
of chondrocyte activity) decline with age, thus reducing cartilage
maintenance and ability to resist mechanical stress. Fibroblast growth
factor 18 (FGF18) is a chondrogenic factor that promotes chondrocyte
proliferation and stabilization of the ’healthy’ anabolic chondrocyte
phenotype. This Proof of Concept (PoC) study in OA patients evaluated
the effects of intraarticular (i.a.) rhFGF18 injection after single ascending
dose (SAD) and multiple ascending dose (MAD) regimens.
Methods: Eligible patients were ≥40 y with symptomatic primary
femorotibial OA of the target knee and radiological disease (Kellgren-
Lawrence grades 2 or 3), with no major knee surgery planned for
≥1 y after ﬁrst injection of study drug; stable oral OA treatments
were permitted. Patients received rhFGF18 or placebo, randomized 3:1
per cohort. Study drug was injected in 10mg, 30mg, or 100mg doses
either once (SAD) or once weekly for 3 weeks in 2 treatment cycles
(MAD). Follow-up and safety reviews occurred weekly over the 4 weeks
postinjection (both cohorts) and at weeks 8, 13, 14, 15, 17, 26, 39
and 52 postinjection (MAD cohorts). Efﬁcacy (MAD cohorts) included
assessment of knee cartilage in selected regions of interest by MRI exam,
joint space width (JSW) of target knee on X-ray, and function and pain
in target knee (WOMAC scores). MRI was performed with coronal SPGR
sequences at baseline, 12, 26, and 52 weeks; X-ray was performed in the
semiﬂexed position at baseline and 52 weeks. All cohorts were assessed
for local and systemic safety. SAD cohorts were assessed for systemic
exposure to rhFGF18.
Results: In SAD cohorts, 18 patients received rhFGF18; 6 received
placebo. In MAD cohorts, 126 received rhFGF18; 42 received placebo.
Age range was 41.4–84.9 y; the BMI range was 15.6–49.0 kg/m 2. As
measured in MAD cohorts, there was a signiﬁcant dose-dependent
anabolic effect of rhFGF18 on cartilage: for the total femorotibial cartilage
volume at 12 months, compared with placebo (−112.69±470.16mm3)
cartilage loss slowed with the lowest dose (−45.20±1117.3mm3), stopped
with the intermediate dose (−1.09±189.93mm3) and reversed with
the highest dose (52.68±175.7mm3; overall p-value=0.0251). Effects
